ILROG Team

Read in the #RedJournal: For the 1st time, consolidation ISRT was randomly compared to IFRT in a phase III trial. Authors argue ISRT/INRT is safe and should thus remain the current standard of care in the setting of CMT of early stage Hodgkin lymphoma. bit.ly/rosenbrock1

Congratulations to our colleague and friend, #ILROG Steering Committee member @umbertoricardi on his #klassbreuraward at @ESTRO_RT this year! So deserved! #lymsm

Should we extend breast cancer screening to Hodgkin Lymphoma patients treated with chemo only?? #radonc #lymphoma @ILROGTeam @becshakir @DavidJCutter

Last hurrah for #ASTRO23 sessions as a Social Champion! QP 19: Modernizing TBI First up - @brandon_imber looking at boom boom versus "big boom" 👉 many tx with definitive intent 👉 80% CR - but can take time! @ILROGTeam

@UofT @Mike_Oertel_MD @HoppeBrad Beatrice Fregonese @MSK_RadOnc @ILROGTeam presenting on primary gastric DLBCL 👉 higher RT doses by disease status 👉 no diff PFS/OS by chemo cycles or pre-RT disease status #ASTRO23

Last but not least for the day: #HemeTeam @ASTRO_org/@ILROGTeam myeloma educational session! 👀 come join heme rad oncs with @ILROGTeam in Beijing! #ASTRO23

@PennyFangMD When to consider surgery? @ILROGTeam steering committee survey for dose in bone + extramedullary #ASTRO23

Another ⁦@ASTRO_org⁩ #ASTRO23 means another CART related RT oral by ⁦@OmranSaifi⁩ Great Job ⁦@MayoFL_RORes⁩ @MayoRadOnc⁩ is proud!!

@ILROGTeam Fantastic use of advanced planning and excellent results without auto, with all G3/4 tox during induction. This ain't your grandparent's mantle RT - highly effective with negligble toxicity! Maybe we should look at transplant-free survival as a new endpoint? 🧐🤔 #ASTRO23

@ILROGTeam Although BV-Nivo did the heavy lifting to CMR, reinforces the benefit of the rational integration of modern RT into evolving systemic therapy paradigms. With the support of groups like @ILROGTeam we can partner with our #HemeTeam colleagues #ASTRO23 @ASH_hematology

👉 @ILROGTeam mini atlas is a fantastic resource for involved site rather than involved field 👉NLPHL behaved more like NHL 👉IMRT planning considerations 👉48 second maliginancies/471 patients #ASTRO23

A little late, but made it to the @ASTRO_org @ILROGTeam joint session on challenging lymphoma cases! First up: challenging cases in abdominal/pelvic lymphomas with Dr. John Plastaras @PennRadOnc #ASTRO23

@ILROGTeam How to sim? 👉 Differences in breast position between arms up/down 👉 Benefits of breath hold 👉 Dose trapping when treating mediastinum/axilla - different priorities between men and women #ASTRO23

Lots to learn at the @ASTRO_org & @ILROGTeam joint session. Practical pearls from @MDAndersonNews @BouthainaDabaja on how to simulate/plan axillary &mediastinal cases for ISRT. Limit dose to the lungs, heart & breasts!Arms down to spare the breast in females. DIBH is your friend.

@ILROGTeam How to plan these cases? ✅ mostly anterior beams ✅ lung V5 matters (sorry @jryckman3) ✅ dose constraints in the @NCCN #ASTRO23

Fantastic and well attended #ASTRO23 @ASTRO_org @ILROGTeam educational session on challenging lymphoma cases featuring all the #lymsm #RadOnc royalty!

Great presentation by @PennRadOnc John Plastaras on the management of challenging cases with RT. @ILROGTeam @ASTRO_org #ASTRO23 @JillGunther @LenaSpecht1

Fun, informative & interactive @ILROGTeam & @ASTRO_org session led by @DrDHodgson. @BouthainaDabaja @JillGunther @LenaSpecht1 John Plastaras #ASTRO23

@ILROGTeam Shifting to a mediastinal case - "lymphoma is like a balloon without invading" 💡 post chemotherapy! So less concerned with chasing microscopic disease, especially as these masses "retract" superiorly #ASTRO23

AutoSCT no more required for low risk r/r cHL > BV-Nivo salvage? @HoppeBrad presented CheckMate 774 in #ASTRO2023 with 95% 3yPFS > RT consolidation with no AutoSCT in 28pts 5-30 ys. @ILROGTeam #radonc #hodgkin